Gamma probe guided biopsy of the sentinel node in malignant melanoma

A multicentre study

S. P. Harlow, D. N. Krag, T. Ashikaga, D. L. Weaver, S. J. Meijer, Brian W. Loggie, K. K. Tanabe, P. Whitworth, J. Kuhn, R. Kusminsky, N. Z. Carp, M. Gadd, M. Rawlings, C. L. Slingluff

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Sentinel lymph node biopsy was attempted in 336 patients with clinically node-negative cutaneous melanoma. All patients were injected with technetium-99m labelled radiocolloid, with 108 patients simultaneously receiving vital blue dye for sentinel node identification. Sentinel lymph nodes were identified in 329 patients, giving a technical success rate of 97.9%. Metastatic disease was identified in 39 (11.9%) of the patients in whom sentinel nodes were found. Patients with negative sentinel nodes were observed and patients with positive sentinel nodes underwent comprehensive lymph node dissection. The presence of metastatic disease in the sentinel nodes and primary tumour depth by Breslow or Clark levels were joint predictors of survival based on Cox proportional hazards modelling. Disease recurrences occurred in 26 (8.8%) patients with negative sentinel lymph nodes, with isolated regional recurrences as the first site in 10 (3.4%). No patients with Clark level II primary tumours were found to have positive sentinel nodes or disease recurrences. One patient with a thin (<0.75mm) Clark level III primary had metastatic disease in a sentinel node. Patients with metastases confined to the sentinel nodes had similar survival rates regardless of the number of nodes involved.

Original languageEnglish
Pages (from-to)45-55
Number of pages11
JournalMelanoma Research
Volume11
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Multicenter Studies
Melanoma
Biopsy
Recurrence
cyhalothrin
Sentinel Lymph Node Biopsy
Technetium
Lymph Node Excision
Neoplasms
Coloring Agents
Survival Rate
Joints
Neoplasm Metastasis
Skin
Survival

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Dermatology

Cite this

Harlow, S. P., Krag, D. N., Ashikaga, T., Weaver, D. L., Meijer, S. J., Loggie, B. W., ... Slingluff, C. L. (2001). Gamma probe guided biopsy of the sentinel node in malignant melanoma: A multicentre study. Melanoma Research, 11(1), 45-55. https://doi.org/10.1097/00008390-200102000-00006

Gamma probe guided biopsy of the sentinel node in malignant melanoma : A multicentre study. / Harlow, S. P.; Krag, D. N.; Ashikaga, T.; Weaver, D. L.; Meijer, S. J.; Loggie, Brian W.; Tanabe, K. K.; Whitworth, P.; Kuhn, J.; Kusminsky, R.; Carp, N. Z.; Gadd, M.; Rawlings, M.; Slingluff, C. L.

In: Melanoma Research, Vol. 11, No. 1, 2001, p. 45-55.

Research output: Contribution to journalArticle

Harlow, SP, Krag, DN, Ashikaga, T, Weaver, DL, Meijer, SJ, Loggie, BW, Tanabe, KK, Whitworth, P, Kuhn, J, Kusminsky, R, Carp, NZ, Gadd, M, Rawlings, M & Slingluff, CL 2001, 'Gamma probe guided biopsy of the sentinel node in malignant melanoma: A multicentre study', Melanoma Research, vol. 11, no. 1, pp. 45-55. https://doi.org/10.1097/00008390-200102000-00006
Harlow, S. P. ; Krag, D. N. ; Ashikaga, T. ; Weaver, D. L. ; Meijer, S. J. ; Loggie, Brian W. ; Tanabe, K. K. ; Whitworth, P. ; Kuhn, J. ; Kusminsky, R. ; Carp, N. Z. ; Gadd, M. ; Rawlings, M. ; Slingluff, C. L. / Gamma probe guided biopsy of the sentinel node in malignant melanoma : A multicentre study. In: Melanoma Research. 2001 ; Vol. 11, No. 1. pp. 45-55.
@article{d24a9c84058849dd95a8048fa2f08f8a,
title = "Gamma probe guided biopsy of the sentinel node in malignant melanoma: A multicentre study",
abstract = "Sentinel lymph node biopsy was attempted in 336 patients with clinically node-negative cutaneous melanoma. All patients were injected with technetium-99m labelled radiocolloid, with 108 patients simultaneously receiving vital blue dye for sentinel node identification. Sentinel lymph nodes were identified in 329 patients, giving a technical success rate of 97.9{\%}. Metastatic disease was identified in 39 (11.9{\%}) of the patients in whom sentinel nodes were found. Patients with negative sentinel nodes were observed and patients with positive sentinel nodes underwent comprehensive lymph node dissection. The presence of metastatic disease in the sentinel nodes and primary tumour depth by Breslow or Clark levels were joint predictors of survival based on Cox proportional hazards modelling. Disease recurrences occurred in 26 (8.8{\%}) patients with negative sentinel lymph nodes, with isolated regional recurrences as the first site in 10 (3.4{\%}). No patients with Clark level II primary tumours were found to have positive sentinel nodes or disease recurrences. One patient with a thin (<0.75mm) Clark level III primary had metastatic disease in a sentinel node. Patients with metastases confined to the sentinel nodes had similar survival rates regardless of the number of nodes involved.",
author = "Harlow, {S. P.} and Krag, {D. N.} and T. Ashikaga and Weaver, {D. L.} and Meijer, {S. J.} and Loggie, {Brian W.} and Tanabe, {K. K.} and P. Whitworth and J. Kuhn and R. Kusminsky and Carp, {N. Z.} and M. Gadd and M. Rawlings and Slingluff, {C. L.}",
year = "2001",
doi = "10.1097/00008390-200102000-00006",
language = "English",
volume = "11",
pages = "45--55",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Gamma probe guided biopsy of the sentinel node in malignant melanoma

T2 - A multicentre study

AU - Harlow, S. P.

AU - Krag, D. N.

AU - Ashikaga, T.

AU - Weaver, D. L.

AU - Meijer, S. J.

AU - Loggie, Brian W.

AU - Tanabe, K. K.

AU - Whitworth, P.

AU - Kuhn, J.

AU - Kusminsky, R.

AU - Carp, N. Z.

AU - Gadd, M.

AU - Rawlings, M.

AU - Slingluff, C. L.

PY - 2001

Y1 - 2001

N2 - Sentinel lymph node biopsy was attempted in 336 patients with clinically node-negative cutaneous melanoma. All patients were injected with technetium-99m labelled radiocolloid, with 108 patients simultaneously receiving vital blue dye for sentinel node identification. Sentinel lymph nodes were identified in 329 patients, giving a technical success rate of 97.9%. Metastatic disease was identified in 39 (11.9%) of the patients in whom sentinel nodes were found. Patients with negative sentinel nodes were observed and patients with positive sentinel nodes underwent comprehensive lymph node dissection. The presence of metastatic disease in the sentinel nodes and primary tumour depth by Breslow or Clark levels were joint predictors of survival based on Cox proportional hazards modelling. Disease recurrences occurred in 26 (8.8%) patients with negative sentinel lymph nodes, with isolated regional recurrences as the first site in 10 (3.4%). No patients with Clark level II primary tumours were found to have positive sentinel nodes or disease recurrences. One patient with a thin (<0.75mm) Clark level III primary had metastatic disease in a sentinel node. Patients with metastases confined to the sentinel nodes had similar survival rates regardless of the number of nodes involved.

AB - Sentinel lymph node biopsy was attempted in 336 patients with clinically node-negative cutaneous melanoma. All patients were injected with technetium-99m labelled radiocolloid, with 108 patients simultaneously receiving vital blue dye for sentinel node identification. Sentinel lymph nodes were identified in 329 patients, giving a technical success rate of 97.9%. Metastatic disease was identified in 39 (11.9%) of the patients in whom sentinel nodes were found. Patients with negative sentinel nodes were observed and patients with positive sentinel nodes underwent comprehensive lymph node dissection. The presence of metastatic disease in the sentinel nodes and primary tumour depth by Breslow or Clark levels were joint predictors of survival based on Cox proportional hazards modelling. Disease recurrences occurred in 26 (8.8%) patients with negative sentinel lymph nodes, with isolated regional recurrences as the first site in 10 (3.4%). No patients with Clark level II primary tumours were found to have positive sentinel nodes or disease recurrences. One patient with a thin (<0.75mm) Clark level III primary had metastatic disease in a sentinel node. Patients with metastases confined to the sentinel nodes had similar survival rates regardless of the number of nodes involved.

UR - http://www.scopus.com/inward/record.url?scp=0035134805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035134805&partnerID=8YFLogxK

U2 - 10.1097/00008390-200102000-00006

DO - 10.1097/00008390-200102000-00006

M3 - Article

VL - 11

SP - 45

EP - 55

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 1

ER -